Non-Criteria or Seronegative Obstetric Antiphospholipid Syndrome?

BACKGROUND: Obstetric antiphospholipid syndrome (Obs-APS) is one of the most commonly identified causes of recurrent pregnancy loss and its accurate diagnosis is a requirement for optimal treatment. Some patients do not fulfill the revised Sapporo classification criteria, the original APS classification criteria, and are considered to be non-criteria Obs-APS. In these patients with non-criteria, there is controversy about their inclusion within the spectrum of APS and eventually their treatment as having Obs-APS. A subset of patients may also have clinical characteristics of Obs-APS even though lupus anticoagulant (LA), anticardiolipin antibodies, and anti-ß2-glycoprotein I (aß2GPI) antibodies are consistently negative. These patients are recognized as seronegative Obs-APS. We reviewed evidence of non-criteria Obs-APS and discuss a case of a woman with a diagnosis of active systemic lupus erythematosus (SLE) and non-criteria Obs-APS with four consecutive pregnancy losses. After an accurate diagnosis the patient received prenatal counseling and benefited from the optimal treatment of Obs-APS that led to a successful pregnancy. The applicability of this successful experience about outcomes in women with non-criteria, or seronegative, Obs-APS is also evaluated.

[Emergency obstetric causes and Immediate Response Team in a secondary hospital]. / Causas de emergencia obstétrica y Equipo de Respuesta Inmediata en un hospital de segundo nivel.

BACKGROUND: The aim of this work is to describe the causes of the obstetric emergency, which motivates the activation of the Immediate Response Team at a second level hospital of the Instituto Mexicano del Seguro Social, which has not an Intensive Care Unit for Adult Patients. METHODS: Retrospective observational study of the causes of obstetric emergency that occurred in the domains of Admission, Hospitalization, Labor, Delivery Room, Operating Room and Recovery of the Hospital General de Zona 53 of the IMSS, during the years 2014 and 2015. RESULTS: In 2014, were attended 3915 women due to obstetric cause; of them, 75 cases were of obstetric emergency and 3276 live births. In 2015, were 4390 women with 3842 live births and 80 cases of obstetric emergency. The main domains where performed the Immediate Response Team were: Labor, Admission and Recovery. In 2014, preeclampsia-eclampsia-Hellp ranked first as a cause of obstetric emergency: 42 cases, also in 2015: 36 cases; followed by obstetric hemorrhage with 28 and 34 cases, respectively. In 2014, there was a maternal death from severe preeclampsia and extensive liver rupture. CONCLUSIONS: Consolidation of Immediate Response Team at a hospital, according to the healthcare environment, it is essential, above all, within the meaning given by staff members.

Introducción: el objetivo es describir las causas de emergencia obstétrica que motivaron la activación del Equipo de Respuesta Inmediata en un hospital de segundo nivel del Instituto Mexicano del Seguro Social que no tiene Unidad de CuidadosIntensivos del Adulto. Métodos: estudio retrospectivo y observacional de las causas de emergencia obstétrica que se presentaron en los dominios de Admisión, Hospitalización, Labor, Expulsión, Quirófano y Recuperación del Hospital General de Zona No. 53 del IMSS, durante los años 2014 y 2015. Resultados: en 2014 se atendieron por causa obstétrica 3915 mujeres, de esta población, hubo 75 casos de emergencia obstétrica y 3276 nacidos vivos. En 2015, fueron 4390 mujeres y 80 casos de emergencia obstétrica con 3842 nacidos vivos. Los principales dominios en donde actuó el Equipo de Respuesta Inmediata en 2014 y 2015, fueron: Labor, Admisión y Recuperación. En 2014, la preeclampsia-eclampsia-Hellp ocupó el primer lugar como causa de emergencia obstétrica con 42 casos, mientras que en 2015 se presentaron 36 casos; la hemorragia obstétrica se presentó en 28 casos en 2014 y 34 casos en 2015. En 2014, hubo una muerte materna por preeclampsia severa y rotura hepática extensa. Conclusiones: la consolidación del Equipo de Respuesta Inmediata, de acuerdo al entorno sanitario, es fundamental, sobre todo, en la acepción otorgada por los integrantes del mismo.

Guías de práctica clínica para la atención del embarazo en mujeres con enfermedades reumáticas autoinmunes del Colegio Mexicano de Reumatología. Parte I / Clinical practice guidelines for the management of pregnancy in women with autoimmune rheumatic diseases of the Mexican College of Rheumatology. Part I

Antecedentes. El embarazo en mujeres con enfermedades reumáticas autoinmunes se asocia a diversas complicaciones maternofetales. El desarrollo de guías de práctica clínica con la mejor evidencia científica disponible puede ayudar a homogeneizar la atención en estas pacientes. Objetivos. Proporcionar recomendaciones respecto al control prenatal, el tratamiento y el seguimiento más efectivo de la mujer embarazada con lupus eritematoso (LES), artritis reumatoide (AR) y síndrome por anticuerpos antifosfolípidos (SAF). Metodología. Para la elaboración de las recomendaciones se conformaron grupos nominales de expertos y se realizaron consensos formales, búsqueda sistematizada de la información, elaboración de preguntas clínicas, elaboración y calificación de las recomendaciones, fase de validación interna por pares y validación externa del documento final teniendo en cuenta los criterios de calidad del instrumento AGREE II. Resultados. Los grupos de trabajo contestaron las 37 preguntas relacionadas con la atención maternofetal en LES, AR y SAF, así como de fármacos antirreumáticos durante el embarazo y la lactancia. Las recomendaciones fueron discutidas e integradas en un manuscrito final y se elaboraron los algoritmos correspondientes. En esta primera parte se presentan las recomendaciones para mujeres embarazadas con LES. Conclusiones. La guía mexicana de práctica clínica para la atención del embarazo en mujeres con LES proporciona recomendaciones e integra la mejor evidencia disponible para el tratamiento y el seguimiento de estas pacientes (AU)

Background. Pregnancy in women with autoimmune rheumatic diseases is associated with several maternal and fetal complications. The development of clinical practice guidelines with the best available scientific evidence may help standardize the care of these patients. Objectives. To provide recommendations regarding prenatal care, treatment, and a more effective monitoring of pregnancy in women with lupus erythematosus (SLE), rheumatoid arthritis (RA) and antiphospholipid antibody syndrome (APS). Methodology. Nominal panels were formed for consensus, systematic search of information, development of clinical questions, processing and grading of recommendations, internal validation by peers, and external validation of the final document. The quality criteria of the AGREE II instrument were followed. Results. The various panels answered the 37 questions related to maternal and fetal care in SLE, RA, and APS, as well as to the use of antirheumatic drugs during pregnancy and lactation. The recommendations were discussed and integrated into a final manuscript. Finally, the corresponding algorithms were developed. We present the recommendations for pregnant women with SLE in this first part. Conclusions. We believe that the Mexican clinical practice guidelines for the management of pregnancy in women with SLE integrate the best available evidence for the treatment and follow-up of patients with these conditions (AU)

Guías de práctica clínica para la atención del embarazo en mujeres con enfermedades reumáticas autoinmunes del Colegio Mexicano de Reumatología. Parte II / Clinical practice guidelines for the management of pregnancy in women with autoimmune rheumatic diseases of the Mexican College of Rheumatology. Part II

Antecedentes. El embarazo en mujeres con enfermedades reumáticas autoinmunes se asocia a diversas complicaciones materno-fetales. El desarrollo de guías de práctica clínica con la mejor evidencia científica disponible puede ayudar a homogeneizar la atención en estas pacientes. Objetivos. Proporcionar recomendaciones respecto al control prenatal, el tratamiento y el seguimiento más efectivo de la mujer embarazada con lupus eritematoso sistémico, artritis reumatoide (AR) y síndrome por anticuerpos antifosfolípidos (SAF). Metodología. Para la elaboración de las recomendaciones se conformaron grupos nominales de expertos y se realizaron consensos formales, búsqueda sistematizada de la información, elaboración de preguntas clínicas, elaboración y calificación de las recomendaciones, fase de validación interna por pares y validación externa del documento final teniendo en cuenta los criterios de calidad del instrumento AGREE II. Resultados. Los grupos de trabajo contestaron las 37 preguntas relacionadas con la atención materno-fetal en lupus eritematoso sistémico, AR y SAF, así como de fármacos antirreumáticos durante el embarazo y lactancia. Las recomendaciones fueron discutidas e integradas en un manuscrito final y se elaboraron los algoritmos correspondientes. En esta segunda parte se presentan las recomendaciones para mujeres embarazas con AR, SAF y el uso de fármacos antirreumáticos durante el embarazo y lactancia. Conclusiones. La guía mexicana de práctica clínica para la atención del embarazo en mujeres con AR y SAF integra la mejor evidencia disponible para el tratamiento y el seguimiento de estas pacientes (AU)

Background. Pregnancy in women with autoimmune rheumatic diseases is associated with several maternal and fetal complications. The development of clinical practice guidelines with the best available scientific evidence may help standardize the care of these patients. Objectives. To provide recommendations regarding prenatal care, treatment, and a more effective monitoring of pregnancy in women with lupus erythematosus, rheumatoid arthritis (RA) and antiphospholipid syndrome (APS). Methodology. Nominal panels were formed for consensus, systematic search of information, development of clinical questions, processing and staging of recommendations, internal validation by peers and external validation of the final document. The quality criteria of the AGREE II instrument were followed. Results. The panels answered 37 questions related to maternal and fetal care in lupus erythematosus, RA and APS, as well as for use of antirheumatic drugs during pregnancy and lactation. The recommendations were discussed and integrated into a final manuscript. Finally, the corresponding algorithms were developed. In this second part, the recommendations for pregnant women with RA, APS and the use of antirheumatic drugs during pregnancy and lactation are presented. Conclusions. We believe that the Mexican clinical practice guidelines for the management of pregnancy in women with RA and APS integrate the best available evidence for the treatment and follow-up of patients with these conditions (AU)

[Rapid Response obstetrics Team at Instituto Mexicano del Seguro Social,enabling factors]. / Equipo de Respuesta Inmediata obstétrico en el Instituto Mexicano del Seguro Social, factores facilitadores.

BACKGROUND: There are barriers and enablers for the implementation of Rapid Response Teams in obstetric hospitals. The enabling factors were determined at Instituto Mexicano del Seguro Social (IMSS) MATERIAL AND METHODS: An observational, retrospective study was conducted by analysing the emergency obstetric reports sent by mobile technology and e-mail to the Medical Care Unit of the IMSS in 2013. Frequency and mean was obtained using the Excel 2010 program for descriptive statistics. RESULTS: A total of 164,250 emergency obstetric cases were reported, and there was a mean of 425 messages per day, of which 32.2% were true obstetric emergencies and required the Rapid Response team. By e-mail, there were 73,452 life threatening cases (a mean of 6 cases per day). A monthly simulation was performed in hospitals (480 in total). Enabling factors were messagés synchronisation among the participating personnel,the accurate record of the obstetrics, as well as the simulations performed by the operational staff. The most common emergency was pre-eclampsia-eclampsia with 3,351 reports, followed by obstetric haemorrhage with 2,982 cases. DISCUSSION: The enabling factors for the implementation of a rapid response team at IMSS were properly timed communication between the central delegation teams, as they allowed faster medical and administrative management and participation of hospital medical teams in the process. CONCLUSION: Mobile technology has increased the speed of medical and administrative management in emergency obstetric care. However, comparative studies are needed to determine the statistical significance.

Clinical practice guidelines for the management of pregnancy in women with autoimmune rheumatic diseases of the Mexican College of Rheumatology. Part I.

BACKGROUND: Pregnancy in women with autoimmune rheumatic diseases is associated with several maternal and fetal complications. The development of clinical practice guidelines with the best available scientific evidence may help standardize the care of these patients. OBJECTIVES: To provide recommendations regarding prenatal care, treatment, and a more effective monitoring of pregnancy in women with lupus erythematosus (SLE), rheumatoid arthritis (RA) and antiphospholipid antibody syndrome (APS). METHODOLOGY: Nominal panels were formed for consensus, systematic search of information, development of clinical questions, processing and grading of recommendations, internal validation by peers, and external validation of the final document. The quality criteria of the AGREE II instrument were followed. RESULTS: The various panels answered the 37 questions related to maternal and fetal care in SLE, RA, and APS, as well as to the use of antirheumatic drugs during pregnancy and lactation. The recommendations were discussed and integrated into a final manuscript. Finally, the corresponding algorithms were developed. We present the recommendations for pregnant women with SLE in this first part. CONCLUSIONS: We believe that the Mexican clinical practice guidelines for the management of pregnancy in women with SLE integrate the best available evidence for the treatment and follow-up of patients with these conditions.

Clinical practice guidelines for the management of pregnancy in women with autoimmune rheumatic diseases of the Mexican College of Rheumatology. Part II.

BACKGROUND: Pregnancy in women with autoimmune rheumatic diseases is associated with several maternal and fetal complications. The development of clinical practice guidelines with the best available scientific evidence may help standardize the care of these patients. OBJECTIVES: To provide recommendations regarding prenatal care, treatment, and a more effective monitoring of pregnancy in women with lupus erythematosus, rheumatoid arthritis (RA) and antiphospholipid syndrome (APS). METHODOLOGY: Nominal panels were formed for consensus, systematic search of information, development of clinical questions, processing and staging of recommendations, internal validation by peers and external validation of the final document. The quality criteria of the AGREE II instrument were followed. RESULTS: The panels answered 37 questions related to maternal and fetal care in lupus erythematosus, RA and APS, as well as for use of antirheumatic drugs during pregnancy and lactation. The recommendations were discussed and integrated into a final manuscript. Finally, the corresponding algorithms were developed. In this second part, the recommendations for pregnant women with RA, APS and the use of antirheumatic drugs during pregnancy and lactation are presented. CONCLUSIONS: We believe that the Mexican clinical practice guidelines for the management of pregnancy in women with RA and APS integrate the best available evidence for the treatment and follow-up of patients with these conditions.

[Incidence of preterm births in the IMSS (2007-2012)]. / Incidencia de nacimientos pretérmino en el IMSS (2007-2012).

BACKGROUND: The birth of a premature child implies an expense raised for the families and the systems of health for the possibilities of visual, auditory disability and problems of learning. The rate of premature births, according to the WHO, goes from 5 to 18 %, for what it was found that it will have to diminish. OBJECTIVE: Knows the behavior of the incident of the childbirth pretérmino in the Mexican Institute of the Social Insurance (IMSS) during the period 2007-2012 in the hospitals of the second and third level of attention ginecoobstétrica. MATERIAL AND METHOD: Descriptive and retrospective study in which there was analyzed the existing information of the cases brought of birth pretérmino in the IMSS (2007-2012). Proved: the total of births was of born 3,135,755 alive, of this 7.7 % they were pretérmino in all the conditions of the Republic, which on having differed with the second level of attention existed 188,715 (6.8%) born pretérmino and the third level of attention (Medical Units of Alta Especialidad, UMAES) with 51,635 (13.7%) born pretérmino (p < 0.05). RESULTS: The total of births was of born 3,135,755 alive, of this 7.7% they were pretérmino in all the conditions of the Republic, which on having differed with the second level of attention existed 188,715 (6.8%) born pretérmino and the third level of attention (Medical Units of Alta Especialidad, UMAES) with 51,635 (13.7%) born pretérmino (p < 0.05). CONCLUSIONS: The strategies to approach the problem of the prematurez are the prevention of the childbirth and the care perinatal to diminish the mortality of the baby and to increase his quality of life for what it is necessary to reinforce the contraceptive Council in the teenagers, to spread the births, as well as the detection and treatment of the infections genitourinarias.

[Causes of maternal mortality in the Instituto Mexicano del Seguro Social, period 2009-2012]. / Causas de mortalidad materna en el Instituto Mexicano del Seguro Social, periodo 2009-2012.

BACKGROUND: The maternal mortality ratio (MMR) has declined slowly, despite the WHO resolved to reduce up to 75 % the maternal mortality from 1990 to 2015. This is why it is necessary to continue the analysis of the causes to strengthen and innovate the courses of action to reduce maternal deaths in our country. METHODS: A retrospective study which included maternal deaths (due to direct and indirect causes) that occurred in the period 2009-2012. The information was obtained from the file of maternal death, which is an Instituto Mexicano del Seguro Social (IMSS) official source. We used the WHO definition of maternal death. Indirect deaths were grouped according to the International Classification of Illnesses (ICI-10). It was used descriptive statistics. RESULTS: The MMR in the IMSS has declined slowly but steadily: in 2012, it was recorded the lowest MMR in this institute: 26.4. However, severe preeclampsia-eclampsia and obstetric hemorrhage were the first and second place, respectively, as direct causes of death. As indirect causes, cardiovascular diseases and malignant neoplasms were the first places (without underestimating the respiratory diseases top figures). CONCLUSIONS: It is necessary to keep doing our efforts to diminish maternal deaths in all levels of medical care at the IMSS. It is a priority to continue education and preconception counseling to women of childbearing age with such diseases.

Introducción: la razón de muerte materna (RMM) ha disminuido lentamente, no obstante que la OMS se propuso reducirla en un 75 % en el período de 1990 a 2015. Por esto es necesario continuar con el análisis de las causas para reforzar e innovar líneas de acción y así disminuir las muertes maternas en nuestro país. Métodos: estudio retrospectivo en el que se incluyeron casos de muerte materna que ocurrieron de 2009 a 2012, por causa directa e indirecta. La información se obtuvo del expediente de muerte materna, el cual es un documento oficial del IMSS. La definición de muerte materna utilizada fue la emitida por la OMS. Las muertes indirectas se agruparon según la décima revisión de la Clasificación Internacional de Enfermedades (CIE-10). Se utilizó estadística descriptiva. Resultados: la RMM en el IMSS ha disminuido en forma lenta pero constante, pues en el 2012 se obtuvo la RMM más baja en la institución (26.4). Sin embargo, la preeclampsia severa-eclampsia y la hemorragia obstétrica ocuparon el primero y segundo lugar. Como causa indirecta, las enfermedades del sistema cardiovascular, y las neoplasias malignas ocuparon los primeros lugares sin subestimar las cifras de las patologías respiratorias, digestivas y endocrinas. Conclusiones: es necesario proseguir con los esfuerzos para disminuir la RMM en todos los niveles de atención médica. Es prioritario continuar con la educación y consejería preconcepcional a mujeres en edad fértil y fortalecer las acciones en la planificación familiar.

Impact of previous lupus nephritis on maternal and fetal outcomes during pregnancy.

Previous reports suggest that renal involvement before pregnancy or active renal disease during pregnancy may be associated with poor fetal and maternal outcomes in systemic lupus erythematosus (SLE) women. We report our experience of fetal and maternal complications in pregnant lupus women with and without previous lupus nephritis. We analyzed the clinical records of pregnant SLE patients attended in a tertiary reference center during a 5-year period. Patients were allocated into two groups according to the presence or absence of previous lupus nephritis. Women were evaluated monthly during pregnancy and at least 1 month postpartum. Maternal and fetal outcomes of pregnancy were abstracted. We included 95 pregnancies in 92 patients. Compared with pregnant women without lupus nephritis (n = 60), pregnancies with previous lupus nephritis (n = 35) were associated with a higher risk of maternal complications (88.5% vs. 43.3%, p = 0.00001), higher rate of lupus flares (54.2% vs. 25%, p = 0.004), and renal flares (45.7% vs. 6.6%, p = 0.00001), but most of which in most instances were reversible. On the other hand, fetal outcome was similar in both groups. Multivariate analysis showed that previous lupus nephritis and active lupus at conception were predictors of adverse maternal outcome. Pregnancies in women with previous lupus nephritis had a higher rate of maternal complications in comparison with those without. However, fetal prognosis was similar in both groups.

[Obstetrical hemorrhage as a maternal death cause in the Instituto Mexicano del Seguro Social during 2011]. / Hemorragia obstétrica, causa de muerte materna. IMSS, 2011.

OBJECTIVE: to describe the clinical data associated to maternal deaths due to fetomaternal bleeding. METHODS: we analyzed 32 of 135 cases of maternal deaths that occurred in the Instituto Mexicano del Seguro Social (IMSS) during 2011. The main inclusion feature was the presence of severe hemorrhage during pregnancy, childbirth or puerperium. RESULTS: obstetric hemorrhage as the underlying cause of maternal death was presented in 65.6 % and in 34.4 % severe obstetric hemorrhage occurred due to different underlying cause of maternal death. The age group with the highest maternal deaths by massive bleeding was the group of 30 to 39 years. The resolution of the pregnancy was by cesarean in most cases. The cases of placenta accrete and uterine atony were others maternal death causes. CONCLUSIONS: the massive bleeding during pregnancy, birth and/or postpartum continues as the second leading cause of maternal mortality in the IMSS. It is necessary to continue training for improving (the performance) in the management of the pregnancy woman with hemorrhage.

[Clinical guideline. Obstetrical hemorrhage in the second half of pregnancy]. / Guía de práctica clínica. Hemorragia obstétrica en la segunda mitad del embarazo.

Pregnancy at older ages and the increased frequency of caesarean births may increase the incidence of diseases associated with obstetric haemorrhage. Obstetric haemorrhage is the second leading cause of maternal mortality, preceded only by preeclampsia-eclampsia in Mexico and the Instituto Mexicano del Seguro Social. In recent years several studies have been conducted to improve the detection, diagnosis and treatment of women at risk of obstetric haemorrhage to reduce maternal and perinatal mortality. The objective of this clinical practice guideline is defining recommendations based in the best available evidence to standardize actions regarding the diagnosis and management of obstetric haemorrhage in hospital units.

[Clinical guideline for detection and diagnosis of hypertensive pregnancy disease]. / Guía de práctica clínica. Enfermedades hipertensivas del embarazo.

Hypertensive disorders in pregnancy (HDP) are the main complication and cause of maternal and perinatal death. Pre-eclampsia represents a 34%, according to the Secretaría de Salud de México. To offer the family physicians tools for the opportune detection and diagnosis of HDP a clinical guideline was developmented. Clinical questions were formulated and structured. A standardized sequence to search for Practice Guidelines, based on the key words: hypertensive disorders in pregnancy, pre-eclampsia. Tripdatabase, MDConsult, National Guideline Clearinghouse, Scottish Intercollegiate Guidelines Network, National Institute for Health and Clinical Excellence were used. In addition, Cochrane Library Plus, Science Direct and OVID were used. Most of the recommendations were taken from guidelines selected and supplemented with the remaining material. The information is expressed in levels of evidence and grade of recommendation according to the characteristics of the study design and type of publications. To reduce morbidity and mortality from HDP health professionals should identify risk factors; conduct a close monitoring and early diagnosis. It is essential to provide information to the pregnant patient on alarm data and behavior to follow. This clinical practice guide offers current evidence for screening and diagnosis of HDP in primary care.

[Correlation index amylase-creatinine clearance to endogenous creatinine clearance in severe preeclampsia]. / Correlación del indice de aclaramiento amilasa-creatinina con la depuración de creatinina endógena en la preeclampsia severa.

INTRODUCTION: Tubular lesion may cause acute renal insufficiency in pregnant patients with severe preeclampsia. OBJECTIVE: To describe the correlation between the amylase/creatinine clearance ratio and endogenous creatinine depuration in pregnant patients with severe preeclampsia. MATERIAL AND METHOD: Transversal study (pilot study) twenty eight women with pregnancies of 20 to 40 weeks complicated by severe preeclampsia were studied. Subjects had serum and urine creatinine and amylase determinations to calculate the amylase/creatinine clearance ratio (%). According to the results, two groups were formed: group A (> 3%) and group B (< or = 3%). The correlation between amylase/creatinine clearance ratio and endogenous creatinine depuration was evaluated. STATISTICAL ANALYSIS: measures of central tendency and dispersion, Student's t-test, Pearson correlation coefficient (r) and linear regression were used. RESULTS: Group A included 23 cases (82%) and group B included 5 cases (18%). Amylase/creatinine clearance ratio (%) for group A was 5.22 +/- 1.6 and for group B was 2.41 +/- 0.41 (p = 0.001). The endogenous creatinine depuration (mL /min. /1.73 m2 SC) for group A was 105.6 +/- 9.71 and for group B was 132.10 +/- 7.95 (p = 0.54). The r between amylase/creatinine clearance ratio and endogenous creatinine depuration for group A was -0.43 and for group B was -0.25. CONCLUSIONS: A moderately significant negative correlation exists between amylase/creatinine clearance ratio and endogenous creatinine depuration.

[Abdominal pregnancy care. Case report]. / Atención del embarazo abdominal. Comunicación de un caso.

Abdominal pregnancies are the implantation of gestation in some of the abdominal structures. This kind of pregnancies represents sevenfold maternal death risk than tubarian ectopic pregnancies, and 90-fold death risk than normal ones. Previous cases have erroneously reported as abscess in Douglas punch, and frequently result in obitus or postnatal deaths. We report a case of a patient with 27 years old, and diagnosis of 25.2 weeks of pregnancy, prior placenta and anhidramnios, referred due to difficult in uterine contour delimitation, easy palpation of fetal parts, cephalic pole in left hypochondrious and presence of mass in hypogastria, no delimitations, pain with mobilization, no transvaginal bleed and fetal movements. Interruption of pregnancy is decided by virtue of severe oligohidramnios, retardation in fetal intrabdominal growth, and recurrent maternal abdominal pain. Surgical intervention was carried out for resolution of the obstetrical event, in which was found ectopic abdominal pregnancy with bed placental in right uterine horn that corresponded to a pregnancy of 30 weeks of gestation. Abdominal pregnancy is still a challenge for obstetrics due to its diagnosis and treatment. Early diagnosis is oriented to prevent an intrabdominal hemorrhage that is the main maternal cause of mortality.

Bromocriptine during pregnancy in systemic lupus erythematosus: a pilot clinical trial.

Bromocriptine (BRC) prevents postpartum flare in lupus patients. However, its potential role in protecting lupus pregnancy from maternal-fetal complications has not been studied. The objective of the study was to explore the role of oral BRC during pregnancy in patients with systemic lupus erythematosus (SLE). Pregnant SLE patients were randomized into two groups: group 1 received BRC 2.5 mg/day and prednisone 10 mg/day; group 2 received prednisone 10 mg/day. These treatments were administered from 25 to 35 weeks of gestation. Prolactin (PRL) levels were determined at 25, 30, and 35 weeks. The SLE Pregnancy Disease Activity Index, maternal-fetal outcome including preterm birth, fetal loss, premature rupture of membrane (PRM), low birth weight, and preeclampsia/eclampsia were evaluated. We studied 20 patients (10 in each group). A significant decrease of PRL levels in group 1 compared to group 2 at week 30 and at week 35 was found. No patients in the BRC group had flares and three from group 2 had SLE activity. None of the patients in group 1 had PRM but three patients in group 2 did. Eighty percent of pregnancies ended in birth at term in group 1 and 50% in group 2. There was no fetal loss in both groups. Mean birth weight was higher in group 1 than in group 2 (P < NS). BRC was well tolerated. This is the first clinical trial of BRC in SLE pregnancy. Our pilot study suggests that BRC may play a role in the prevention of maternal-fetal complications, such as PRM, preterm birth, and active disease.

Prolactin levels are associated with lupus activity, lupus anticoagulant, and poor outcome in pregnancy.

High prolactin (PRL) levels seem to be associated with active systemic lupus erythematosus (SLE) during pregnancy. However, the association of activity, lupus anticoagulant (LA), and pregnancy outcome has not been analyzed. The objective of this study was to analyze the association among SLE activity, LA, and maternal-fetal outcome. We studied 15 pregnant SLE patients (ACR criteria), 4 of them with associated antiphospholipid syndrome (APS), and 9 healthy pregnant women. All patients were evaluated monthly with the following determinations: (a) SLE activity using modified-systemic lupus activity measurement (m-SLAM), (b) LA, and (c) PRL serum levels. Healthy controls were evaluated each trimester. Prematurity, fetal loss, low birth weight, and preeclampsia were evaluated. Chi-square test, Fisher's exact test, Student's t-test, Pearson correlation, and ANOVA were performed. The mean age of SLE patients was 30 +/- 4.9 years and 27.1 +/- 3.7 years in controls. High PRL levels were found during the second and third trimester in SLE patients in comparison with controls (186.2 +/- 54.02 ng/mL versus 119.6 +/- 31.1 ng/mL (P < 0.01) and 177.4 +/- 48.6 ng/mL versus 158.3 +/- 31.5 ng/mL. A significant linear correlation between PRL, m-SLAM, and LA in association with poor maternal-fetal outcome was observed. LA and PRL conferred risk for poor pregnancy outcome. Our study indicates for the first time a strong association among PRL, LA, SLE activity, and poor pregnancy outcome. Close rheumatologic and obstetric monitoring is mandatory in SLE pregnancy in order to avoid obstetric complications.

[Estrogen therapy effect in arterial tension in postmenopausal women]. / Efecto del tratamiento con estrógenos en la tensión arterial de mujeres posmenopáusicas.

INTRODUCTION: Experimental studies have shown that estrogens prevent deposit of cholesterol in arteries, have effect upon the endothelial function (to prevent contraction of smooth muscle), and enlarge the vascular tone or vasodilatation. OBJECTIVE: To determine changes in arterial pressure before and after use of estrogen-therapy. MATERIAL AND METHODS: A descriptive study was carried out follow-up during 8 weeks in Obstetric and Gynecologic Hospital (No. 3), Instituto Mexicano del Seguro Social. We included 250 postmenopausal women with prescribed estrogen-therapy. Arterial tension was determined before and after therapy; descriptive statistics and student t test (value, p < 0.05) was employed. RESULTS: Menopause was present in a mean of age of 46 +/- 4.2 years (M +/- SD); height was 1.53 +/- 0.6 m; corporal weight, 60.9 +/- 10.2 kg, and hip-waist index was 81.3 +/- 5.4. Mean arterial tension before estrogen-therapy was 90.2 +/- 10.0 mmHg, and after, 85.7 +/- 9.6 mmHg (p < 0.05). CONCLUSIONS: There is evidence of estrogen-therapy vasodilatation and hypotension effects, with clinical changes statistically significative; however is recommendable that such estrogenic therapy must be individualized and attended in slender form. Hormonal therapy (estrogens) has benefits in arterial tension of postmenopausal women.